Shionogi Showcases Infectious Disease Innovations at IDWeek 2024

Shionogi Inc., the U.S. branch of Shionogi & Co., Ltd., based in Osaka, Japan, will present 22 scientific contributions at IDWeek 2024, scheduled for October 16-19 in Los Angeles, California. Among these, 13 presentations will focus on Fetroja® (cefiderocol), with a highlight being a new real-world evidence study involving about 1,000 patients from the U.S. and Europe. Named PROVE, this is the most extensive study to date evaluating cefiderocol usage in hospitalized patients suffering from severe Gram-negative infections, most of which were resistant to carbapenem antibiotics.

Significantly, Shionogi will deliver two oral presentations featuring nonclinical data that assess cefiderocol's efficacy against some challenging bacterial strains resistant to antibiotics. These will also explore its effectiveness both as a standalone treatment and in combination with xeruborbactam, an investigational beta-lactamase inhibitor added to Shionogi’s pipeline following the acquisition of Qpex Biopharma, Inc. in 2023.

Nate McCutcheon, President and CEO of Shionogi Inc., emphasized the company's dedication to evaluating real-world outcomes for its antibiotics treating Gram-negative infections. He highlighted the importance of meeting educational and practical needs for healthcare providers and patients. McCutcheon also announced plans to expand Shionogi’s global infectious disease and antimicrobial research operations in the U.S., with the establishment of the company’s first U.S.-based discovery lab in San Diego through Qpex.

Michael N. Dudley, President and CEO of Qpex, will deliver the keynote address at the Society of Infectious Diseases Pharmacists Annual Meeting, held concurrently with IDWeek.

In addition to the scientific presentations, Shionogi will offer the infectious disease community a chance to combat antimicrobial resistance (AMR) through a new version of its award-winning AMR Warrior experience. Visitors to Shionogi’s Booth #322 can create their own AMR Warrior image to spread awareness.

The company will also host a sponsored Learning Lounge on Friday, October 18, featuring Thomas Lodise, Professor at the Albany College of Pharmacy and Health Sciences, who will present “Fetroja® (cefiderocol): An Overview of In Vitro, Clinical, and Real-world Data.”

Shionogi's cefiderocol presentations at IDWeek include:
- Oral #513: Cefiderocol's in vitro activity against Enterobacterales non-susceptible to beta-lactam-beta-lactamase inhibitor combinations.
- Poster #650: Comparison of cefiderocol and other agents against Enterobacterales isolates from hospitalized pneumonia patients, based on data from the SENTRY Surveillance Program (2020-2022).
- Poster #1099: Correlation between cefiderocol's in vitro activity and in vivo efficacy against Acinetobacter baumannii strains.
- Poster #1100: Activity against global isolates of Stenotrophomonas maltophilia (2020-2023).
- Poster #1360: Efficacy against carbapenem non-susceptible Enterobacterales causing infections in U.S. hospitals (2020-2023).
- Poster #1361: Efficacy against Pseudomonas aeruginosa, including resistant subsets from U.S. hospitals (2020-2023).
- Poster #1362: Activity against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (2020-2023).
- Poster #1363: Activity against clinical Enterobacterales isolates with metallo-beta-lactamase genes in U.S. and European hospitals (2020-2023).
- Poster #1364: Activity against Pseudomonas aeruginosa clinical isolates carrying metallo-beta-lactamase genes in U.S. and European hospitals (2020-2023).
- Poster #1472: Efficacy against carbapenemase-producing Enterobacterales.
- Poster #1475: Real-world effectiveness and safety of cefiderocol in treating serious Gram-negative bacterial infections.
- Poster #1484: Comparison of cefiderocol and other agents against non-fermentative Gram-negative bacilli from patients with pneumonia (2020-2022).
- Poster #1530: Evaluation of cross-resistance between cefiderocol and other inhibitor combinations against Pseudomonas aeruginosa isolates from U.S. medical centers.

Xeruborbactam data presentations at IDWeek include:
- Oral #514: Impact of xeruborbactam on cefiderocol's activity against Acinetobacter baumannii.
- Poster #1110: Impact on cefiderocol's activity against Enterobacterales with reduced susceptibility.

Shionogi's presence at IDWeek underscores its ongoing commitment to addressing global health challenges, with a focus on infectious diseases, including antimicrobial resistance, and advancing the development of innovative therapeutic solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!